期刊文献+

二氢嘧啶脱氢酶活性在食管癌化疗中的临床研究

Clinical study of dihydropyrimidine dehydrogenase activity on chemotherapy of esophageal carcinoma
下载PDF
导出
摘要 目的探讨食管癌患者血二氢嘧啶脱氢酶(dihydropyrimidine dehydrogen-ase,DPD)活性与一般临床资料、毒副作用及疗效的相关性。方法采用高效液相色谱法(high performanceliquidchromatog-raphy,HPLC)测定81例食管癌患者化疗前血DPD活性,行DLF方案化疗,同时观察化疗不良反应和疗效。结果血DPD活性在食管癌患者中呈正态分布。其与患者的一般临床资料无相关性,P>0.05;与5-FU致恶心呕吐、骨髓抑制、腹泻、口腔黏膜炎和疲劳等有相关性,P<0.05;与化疗疗效没有相关性,r=-0.81,P=0.11。结论血DPD活性与5-FU相关毒性呈负相关,与一般临床资料及化疗疗效无相关性。 OBJECTIVE:To explore the relationship between DPD activity and the common clinical data, treatment response, adverse events in esophageal cancer patients, METHODS: The DPD activity in blood with e sophageal cancer 81 patients was detected by high-performance liquid chromatography (HPLC) before chemotherapy. The patients with esophageal carcinoma received DLF regimen. Treatment response and adverse events in the patients were assessed. RESULTS: The DPD activity in blood was normally distributed in esophageal cancer patients. The DPD activity in blood had no correlation with common clinical data of the patients, P〉0. 05. The 5-FU associated toxicities had a negative relationship with DPD activity in blood, P〈0. 05. The DPD activity in blood had no relation with treatment response, r=-0. 81, P=0.11. CONCLUSIONS: The DPD activity in blood negatively correlates with 5-FU associated toxieities. The DPD activity in blood does not correlates with common clinical data and treatment response in esophageal cancer patients.
出处 《中华肿瘤防治杂志》 CAS 2006年第23期1811-1813,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 二氢尿嘧啶脱氢酶(NADP) 食管肿瘤 药物疗法 dihydrouracil dehydrogenase esophageal neoplasms drug therapy
  • 相关文献

参考文献8

  • 1Jiang W Q,Lu Z H,He Y J,et al.Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma:implication in 5-fluorouracil based chemotherapy[J].Clin Cancer Res,1997,3 (3):395-399.
  • 2Nozawa H,Tsukui H,Nishida K,et al.Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma[J].Cancer Chemother Pharmacol,2002,49(4):267-273.
  • 3王国强,周志伟,万德森,潘志忠,李苏.血二氢嘧啶脱氢酶活性与结直肠癌临床病理参数关系的研究[J].大肠肛门病外科杂志,2004,10(3):180-182. 被引量:3
  • 4Van Kuilenburg A B,De Abreu R A,Van Gemip A H.Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency[J ].Ann Clin Biochem,2003,40 (Pt1):41-45.
  • 5Di Paolo A,Danesi R,Falcone A,et al.Relationship between 5-fluorouracil disposition,toxicity and dihydropyrimidine dehydrogenase activity in cancer patients[J].Ann Oncol,2001,12(9):1301-1306.
  • 6周志伟,王国强,万德森,潘志忠,李苏,陈功,廖海.二氢嘧啶脱氢酶活性与结直肠癌患者5-FU辅助化疗毒性关系的研究[J].癌症,2004,23(z1):1512-1516. 被引量:6
  • 7Ichikawa W,Uetake H,Shirota Y,et al.Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine based chemotherapy for metastatic colorectal cancer[J].Clin Cancer Res,2003,9(2):786-791.
  • 8肖菊香,韩梅,李莉,朱娟,陈利红,白沛松.结直肠癌组织中二氢嘧啶脱氢酶的表达及其临床意义[J].中华医学杂志,2005,85(30):2136-2139. 被引量:1

二级参考文献20

  • 1Lu ZH, Robert BD. Dihydropyrimidine Dehydrogenase Activity and Fluorouracil Chemotherapy. Journal of Clinical Oncology, Edtorial,1994, 12(11):22392242.
  • 2Lu ZH,Zhang RW,Robert BD.Dihydropyrimidine Dehy-drogenase Activity in Human Peripheral Blood Mononu-clear Cells and Liver: Population Characteristics, Newly Identified Deficient Patients, and Clinical Implication in 5-Fluorouracil Chemotherapy. Cancer Research, 1993, 53(11): 5433-5438.
  • 3Barry EH,Song R,Soong SJ,et al.Ralationship between Dihydropyrimidine Dehydrogenase Activity and Blood 5-Fluorouracil Levels with Evidence for Circadian Variation of Enzyme Activity and Blood Drug Levels in Cancer Patients Receiving 5-Fluorouracial by Protracted Continuous Infusion. Cancer Research , 1990, 50 (1):197-201.
  • 4Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al. Correlation between Uracil and Dihydrouracil Blood Ratio, Fluorouracil(5-FU) Pharmacokinetic Parameters, and Tolerance in Patients with Advanced colorectal Cancer : A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage. Journal of Clinical Oncology, 1999, 17(4): 1105-1110.
  • 5Terashima M, Irinoda T, Fujiwara H, et al. Roles of Thymidylates and dihydropyrimidine dehydrogenase in Tumor Progression and Sensitivity to 5-Fluorouracil in Human Gastric Cancer. Anticancer Research, 2002, 22(2A): 761-768.
  • 6Hoff PM,Royce M,Medgyesy D,et al.Oral Fluoropyri-midines. Semin Oncology, 1999, 26(12): 640-646.
  • 7Mcleod HL,Sluden J,Murray GI,et al.Characterization of dihydropyrimidine dehydrogenase in human colorectal tumors. British Journal of Cancer, 1998, 77 (3): 461-465.
  • 8[1]Johnson MR, Hageboutros A, Wang K, et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil [J]. Clin Cancer Res,1999,5(8): 2006-2011.
  • 9[2]van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD)deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene [J].Clin Cancer Res, 2000, 6(12): 4705 -4712.
  • 10[3]Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU) -related toxicity compared with controls [J]. Clin Cancer Res, 2001, 7(9):2832 - 2839.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部